SIGLEC1 and cancer: In line, Affandi and co-workers reported a dose-dependent induction of CD169 expression by IFN-α in CD14+ monocytes, as well as higher human leukocyte antigen (HLA)-DR expression in CD169+ monocytes among peripheral blood mononuclear cells (PBMCs) of cancer patients (106).